Heart failure drug combo shows promise for leaky valve patients

NCT ID NCT05991284

Completed Disease control Sponsor: Ziekenhuis Oost-Limburg Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding sacubitril-valsartan to standard care helps people with heart failure (with preserved pumping ability) and a leaky mitral valve. 84 participants were randomly assigned to get the drug or standard care alone. Researchers measured heart function and exercise capacity after six months to see if the drug improves blood flow and symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacubitril-valsartan
What this could lead to: If it works, this could improve heart function and exercise capacity in patients with a specific type of heart failure and leaky mitral valve.
What could go wrong: This is a small, completed phase 4 trial with 84 participants. The results may not apply to all heart failure patients, and the drug may cause side effects like low blood pressure or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FUNCTIONAL MITRAL REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure mitral valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FUNCTIONAL MITRAL REGURGITATION HEART FAILURE WITH PRESERVED EJECTION FRACTION

Contacts and locations

Locations

Ziekenhuis Oost-Limburg

Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.